RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Newron Pharmaceuticals SpA Stock

Newron Pharmaceuticals SpA Employees 2025

Newron Pharmaceuticals SpA Employees

26

Ticker

NWRN.SW

ISIN

IT0004147952

WKN

A0LF18

In 2025, Newron Pharmaceuticals SpA employed 26 people, a 0% change from the 26 number of employees in the previous year.

Newron Pharmaceuticals SpA Aktienanalyse

What does Newron Pharmaceuticals SpA do?

Newron Pharmaceuticals SpA is an international biopharmaceutical company specializing in the development of novel products for the treatment of central nervous system (CNS) disorders. The company is headquartered in Italy and is listed on the SIX Swiss Exchange. The history of Newron Pharmaceuticals SpA dates back to 1996 when it was founded by a team of experienced pharmaceutical experts. Since then, the company has become a leading player in the development of therapies for rare neurological disorders. The focus is particularly on diseases such as Parkinson's and Rett syndrome, as well as other neurological disorders. Newron Pharmaceuticals SpA's business model is based on the research and development of novel drugs in the field of the central nervous system. The company typically conducts research and development in its own laboratories and collaborates closely with external experts and institutions to develop innovative therapies. The goal is to develop patient-oriented, innovative drugs and successfully bring them to market. The company has several product candidates in various stages of development, including Xadago® (Safinamide), an approved drug for the treatment of Parkinson's. Similarly, an orally administered drug is being tested in phase III of clinical development with the aim of improving motor symptoms in Parkinson's. Another important product candidate of Newron Pharmaceuticals SpA is Sarizotan, an innovative drug for the treatment of Rett syndrome, a rare neurological disease that primarily affects girls. The company has entered into a partnership with the American company Rett Syndrome Research Trust (RSRT) to promote further development of the drug. In addition to researching and developing new drugs, Newron also actively works on advancing existing treatment approaches. For example, collaborations with academic institutions are used to incorporate new knowledge from the fields of molecular biology and genetics to further expand existing therapeutic approaches. The company follows an integrative approach, focusing on collaboration between research and development teams, clinical experts, patient organizations, and regulatory authorities. The goal is to treat patients with novel and effective therapies. Overall, Newron Pharmaceuticals SpA is an internationally operating biopharmaceutical company dedicated to researching and developing novel therapies in the field of the central nervous system. Through its innovative research and development activities and close collaboration with experts, institutions, and patient organizations, the company significantly contributes to the advancement of treatment options for neurological disorders. Newron Pharmaceuticals SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Newron Pharmaceuticals SpA's Employee Base

Newron Pharmaceuticals SpA's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Newron Pharmaceuticals SpA's operational capacity and future potential.

Year-to-Year Comparison

Assessing Newron Pharmaceuticals SpA's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Newron Pharmaceuticals SpA's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Newron Pharmaceuticals SpA’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Newron Pharmaceuticals SpA stock

How many employees does Newron Pharmaceuticals SpA have this year?

Newron Pharmaceuticals SpA has 26 undefined employees this year.

How many employees did Newron Pharmaceuticals SpA have compared to the previous year?

Compared to the previous year, Newron Pharmaceuticals SpA had 0% more employees.

What impact did the number of employees have on the company Newron Pharmaceuticals SpA?

The number of employees has a direct impact on the efficiency and productivity of Newron Pharmaceuticals SpA. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Newron Pharmaceuticals SpA?

The number of employees can also have an impact on investors of Newron Pharmaceuticals SpA, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Newron Pharmaceuticals SpA affect the company?

An increase in equity of Newron Pharmaceuticals SpA can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Newron Pharmaceuticals SpA's equity affect the company?

A reduction in equity of Newron Pharmaceuticals SpA can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Newron Pharmaceuticals SpA?

Some factors that can influence the equity of Newron Pharmaceuticals SpA include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Newron Pharmaceuticals SpA so important for investors?

The equity of Newron Pharmaceuticals SpA is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Newron Pharmaceuticals SpA influence the company?

The number of employees at Newron Pharmaceuticals SpA can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Newron Pharmaceuticals SpA evolved in recent years?

In recent years, the number of employees at Newron Pharmaceuticals SpA has changed by 0.

How many employees does Newron Pharmaceuticals SpA currently have?

Newron Pharmaceuticals SpA currently has 26 undefined employees.

Why is the number of employees important for investors of Newron Pharmaceuticals SpA?

The number of employees is important for investors of Newron Pharmaceuticals SpA as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Newron Pharmaceuticals SpA take to change the number of employees?

To change the number of employees, Newron Pharmaceuticals SpA can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Newron Pharmaceuticals SpA pay?

Over the past 12 months, Newron Pharmaceuticals SpA paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Newron Pharmaceuticals SpA is expected to pay a dividend of 0 EUR.

What is the dividend yield of Newron Pharmaceuticals SpA?

The current dividend yield of Newron Pharmaceuticals SpA is .

When does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Newron Pharmaceuticals SpA?

Newron Pharmaceuticals SpA paid dividends every year for the past 0 years.

What is the dividend of Newron Pharmaceuticals SpA?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Newron Pharmaceuticals SpA located?

Newron Pharmaceuticals SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Newron Pharmaceuticals SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Newron Pharmaceuticals SpA from 3/9/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 3/9/2025.

When did Newron Pharmaceuticals SpA pay the last dividend?

The last dividend was paid out on 3/9/2025.

What was the dividend of Newron Pharmaceuticals SpA in the year 2024?

In the year 2024, Newron Pharmaceuticals SpA distributed 0 EUR as dividends.

In which currency does Newron Pharmaceuticals SpA pay out the dividend?

The dividends of Newron Pharmaceuticals SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Newron Pharmaceuticals SpA

Our stock analysis for Newron Pharmaceuticals SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Newron Pharmaceuticals SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.